格隆汇10月9日｜药明康德(603259.SH)公告称，公司于2025年10月8日通过大宗交易出售所持有的药明 合联3030万股股票，约占其当前总股本的2.47%，成交金额约23.46亿港元。本次出售药明合联股票的投 资净收益对公司2025年度税后净利润的影响约为人民币16.79亿元，占公司最近一期(2024年度)经审计归 属母公司股东净利润的比例超过10%。2025年度累计出售药明合联股票的投资净收益对公司2025年度税 后净利润的影响约为人民币43.51亿元。 ...

Core Viewpoint - The company plans to sell a significant number of shares in various companies based on market conditions, which is expected to yield substantial profits exceeding 50% of its audited net profit from the last year [1] Group 1: Share Sales - The company intends to sell 8.686 million shares of Guizhou Yibai Pharmaceutical Co., Ltd. [1] - The company plans to sell 970,600 shares of Aorui De Optoelectronics Co., Ltd. [1] - The company will sell 7,716 shares of China Ping An Insurance (Group) Company [1] - The company aims to sell 4.7122 million shares of Hunan Erkang Pharmaceutical Co., Ltd. [1] Group 2: Financial Impact - The estimated profit from the sale of these shares, after deducting holding costs and related taxes, is projected to account for over 50% of the company's audited net profit from the previous year [1]